Altmetrics
Downloads
248
Views
135
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
20 April 2023
Posted:
21 April 2023
You are already at the latest version
Technology | Principle | Advantage | Disadvantage |
AfBPP | Affinity of target proteins to active small molecules on stationary phases | 1. No bias; 2. Systematic study of total protein; 3. It can enrich the target and is suitable for identification of low abundance proteins. |
1. A detailed understanding of the structure-activity relationship of active molecules is required; 2. Chemical derivatization of active molecules is required; 3. Targets with low abundance and low affinity are easy to be washed off; 4. Probes usually cannot enter cells. |
ABPP | The target protein forms a covalent bond with a covalent small molecule. | 1. No bias; 2. Systematic study of whole protein; 3. It can enrich the target and is suitable for identification of low abundance proteins; Grasp low affinity targets; 4. Probes usually get into cells. |
1. A thorough understanding of the structure-activity relationship of active molecules is required; 2. Chemical derivatization of active molecules is required; 3. Non-specific covalent binding is easy to occur. |
TPP | The thermal stability of the target protein increases after binding with small molecules and it is not easy to precipitate | 1. No bias; 2. Systematic study of whole protein; 3. No derivations of small active molecules are required. |
1. Limited effect on extreme conditions, such as heat insensitivity or heat unstable proteins; 2. Further measures should be taken to reduce the complexity of samples so as to realize the identification of low abundance proteins. |
DARTS | The stability of the target protein increases after binding with small molecules and is not easily degraded by enzymes | 1. No bias; 2. Systematic study of whole protein; 3. No derivations of small active molecules are required. |
1. The protein that is not sensitive to enzyme digestion has limited effect; 2. Further measures should be taken to reduce the complexity of samples so as to realize the identification of low abundance proteins. |
Seq_ID | Medicine | Personalized tag | Approval time | Molecular formula | Mechanism of action | Disease |
1 | Crizotinib | ALK+ | 2014 | ALK inhibitor | Metastatic non-small cell lung cancer with ALK or ROS1 positive | |
2 | Ceritinib | ALK+ | 2014 | ALK inhibitor | Non-small-cell lung cancer | |
3 | Alectinib | ALK+ | 2015 | ALK inhibitor | Non-small-cell lung cancer | |
4 | Brigatinib | ALK+ | 2017 | ALK inhibitor | Non-small-cell lung cancer | |
5 | Lorlatinib | ALK+ is positive | 2018 | A dual-target inhibitoror of ALK/ROS1 | Non-small-cell lung cancer | |
6 | Gefitinib | EGFR | 2003 | EGFR inhibitor | Non-small-cell lung cancer | |
7 | Erlotinib | EGFR | 2004 | EGFR inhibitor | Non-small-cell lung cancer | |
8 | Afatinib | EGFR | 2013 | EGFR inhibitor | Non-small-cell lung cancer | |
9 | Osimertinib | EGFR | 2015 | EGFR inhibitor | Non-small-cell lung cancer |
Seq_ID | Natural products | Main Sources | Molecular formula | Related Gene | Disease |
1 | Trabectedin | Ecteinascidia turbinata | BRCA1, BRCA2 | Soft tissue sarcoma, Breast cancer |
|
2 | Vincristine | Catharanthus roseus | CYP3A enzymes, ABC transporters |
Leukemias, Lymphomas, Brain tumors, Solid tumors |
|
5 | Paclitaxel | Taxus baccata Linn | ABCB1 G2677T/A mutation | Ovarian cancer | |
3 | Gigantol | Dendrobium draconis | CD133, ALDH1A1 | Non-small-cell lung cancer | |
6 | Chrysotoxine | Dendrobium pulchellum | ABCG2 | Lung cancer |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated